Invention Grant
- Patent Title: Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
-
Application No.: US12782376Application Date: 2010-05-18
-
Publication No.: US08367063B2Publication Date: 2013-02-05
- Inventor: William J. Boyle , Eugene Medlock , John K. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
- Applicant: William J. Boyle , Eugene Medlock , John K. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
- Applicant Address: US CA Thousand Oaks US NJ Princeton
- Assignee: Amgen, Inc.,Medarex, Inc.
- Current Assignee: Amgen, Inc.,Medarex, Inc.
- Current Assignee Address: US CA Thousand Oaks US NJ Princeton
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00 ; C07K16/24 ; C07K16/00
Abstract:
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Public/Granted literature
- US20110052604A1 Human Anti-OPGL Neutralizing Antibodies as Selective OPGL Pathway Inhibitors Public/Granted day:2011-03-03
Information query
